In the fight against leukemia and lymphoma, T cells are a powerful tool. But T cell therapies are notoriously fraught with challenges that can be difficult to overcome. We introduce CDR3’s unique, patented technology that creates a permanent, self-renewing source of T cells directed against diseased cells over the lifetime of a patient. It connects a much-needed therapy to the lives of people who need it. And while we can make this revolutionary new cancer treatment, we need to make the treatment possible. Through your investment in CDR3, you’ll see pain begin to disappear, lives start to improve, and your portfolio produce a return – all while helping humanity in a positive new direction.